Table 4.

Estimation of average treatment effects and potential outcome mean of RAAS treatment on death after ESRD by diabetic groups

Model for diabetic patients	Treatments	RD	LL	UL	NNT	LL	UL
ATE	RAAS1 vs non-RAAS	0.062	−0.037	0.161	16.1	−9.5	41.7
	RAAS2 vs non-RAAS	−0.059	−.0129	0.0112	−16.9	−36.9	3.18
		Risk	LL	UL	RR	LL	UL
POM	Non-RAAS	0.681	0.659	0.704	1
	RAAS1	0.743	0.647	0.839	1.091	0.945	1.236
	RAAS2	0.622	0.555	0.689	0.913	0.810	1.016
Model for non-diabetic patients	Treatments	RD	LL	UL	NNT	LL	UL
ATE	RAAS1 vs non-RAAS	0.124	−0.059	0.306	8.1	−3.8	19.9
	RAAS2 vs non-RAAS	−0.121	−0.333	0.092	−8.3	−22.9	6.3
		Risk	LL	UL	RR	LL	UL
POM	Non-RAAS	0.596	0.576	0.617	1
	RAAS1	0.719	0.539	0.901	1.209	0.909	1.509
	RAAS2	0.475	0.264	0.687	0.798	0.435	1.162

ATE Average treatment effect, LL Lower limit, POM Potential outcome mean, RAAS1 Duration use of 0.25–1 year, RAAS2 Duration use of >1 year, RD Risk difference, RR Rate ratio, UL Upper limit